# Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

> **NCT00203099** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Relapse Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate, N-Acetylcysteine

## Key facts

- **NCT ID:** NCT00203099
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-08
- **Final completion:** 2008-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203099, "Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00203099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*